Search bioRxiv⌕ Search

Biology subjects

Govender, K.

Publications and source records attributed to Govender, K..

5 recordsLinked to original sources

Preliminary report on the molecular epidemiology of mpox, South Africa 2024

Mpox is an emerging viral infection and has since May 2022 been reported in a multi-country outbreak involving predominantly previously non-endemic countries. In addition, the number of cases of mpox is also rising in some endemic countries in Western and Central Africa. The disease is a notifiable medical condition in South Africa, with no cases reported before 2022. However, in 2022, coinciding with the peak of a multi-country mpox outbreak, five mpox cases were diagnosed in the country. Genomic sequencing and analysis revealed the presence of a monkeypox virus variant, which was circulating during the multi-country outbreak, namely Clade IIb sub-lineage B.1.7 (hMPXV). After the fifth case was reported in 2022, there were no cases detected for the following 20 months. In May 2024, mpox cases were again detected in South Africa leading to concerns that the virus may have been silently transmitting in the country since 2022. Genomic sequencing and analysis for 22 mpox cases reported during May to September 2024, were compared with sequences obtained from mpox cases reported in South Africa in 2022, and cases that have been reported globally. It was found that the sequences of the 2024 cases analysed in this study, clustered with Clade IIb hMPXV and sub-lineage B.1.20 and B.1.6 sequences. The results indicate that the detection of mpox cases in South Africa was an extension of the ongoing multi-country outbreak. Detection of different sub-lineages of hMPXV indicates reintroductions of the virus in the country since 2022, with local transmission of Clade IIb B1.20 hMPXV.

microbiology↗

Enhancement and validation of the antibiotic resistance prediction performance of a cloud-based genetics processing platform for Mycobacteria

Tuberculosis remains a global health problem. Making it easier and quicker to identify which antibiotics an infection is likely to be susceptible to will be a key part of the solution. Whilst whole-genome sequencing offers many advantages, the processing of the genetic reads to produce the relevant public health and clinical information is, surprisingly, often the responsibility of the end user which inhibits uptake. Here we characterise how well a freely-available tool we have developed, gnomonicus, predicts the antibiotic resistance profile of a sample (given its variant call file) using our implementation of the second edition of the WHO catalogue of resistance-associated variants (WHOv2). To facilitate this, we have constructed a Diverse Testset of 2,663 publicly-available M. tuberculosis samples which have both genetic and drug susceptibility testing (DST) data. We have chosen to apply the catalogue such that our tool will return a result of (i) Fail if there are insufficient reads at a genetic locus associated with resistance, (ii) Unknown if a genetic variant in a resistance gene not listed in the catalogue is encountered and (iii) Resistant if three or more short-reads support the presence of a resistance-associated variant. The last step increases the sensitivity for all 15 antibiotics but only reaches significance in a few in our testset. Comparing our results to those of TB-Profiler, an existing tool, highlights the different design choices and demonstrates the performance of both tools on our Diverse Testset is comparable. By only considering high confidence DST results we show that gnomonicus, in combination with our translation of WHOv2, achieves sensitivities and specificities in excess of 95% for both isoniazid and rifampicin. Impact StatementWhole genome sequencing clinical samples taken from patients with tuberculosis is a potentially fast and accurate method for determining to which antibiotics the infection will be susceptible. Two barriers need to be overcome; the first, which is knowing which mutations are associated with resistance (or not) to a range of antibiotics is well on the way to be solved thanks to the efforts of the World Health Organization (WHO) who have published extensive catalogues containing lists of such mutations. The second barrier is that the processing of the raw genetic files remains a largely manual process overseen by bioinformaticians. Here we describe gnomonicus, our open-source AMR prediction tool, and report the performance of our translation of the second edition of the WHO catalogue using a carefully designed publicly-available dataset of 2,663 M. tuberculosis samples. We hope that not only will this tool be useful but also that this dataset will be used by other researchers to facilitate comparisons between pipelines, approaches and tools. Data SummaryThe attendant GitHub repository1 allows gnomonicus to be rerun on all 2,663 samples in the Diverse Testset; it therefore includes instructions, the necessary input files (all the variant call files, the version of the WHOv2 catalogue and a link to the H37Rv GenBank file used in this study) and also the output JSON files. The ENA accession numbers for all 2,663 samples (including a bash script to download them) and their corresponding phenotypic drug susceptibility testing results are included with the intention that people can either reproduce our results, or use the same dataset for other analyses. The JSON files output by TB-Profiler have also been added for comparison. The repository contains a series of Juypter notebooks containing Python3 code that allows the user to discover and parse the output JSON files from either tool and save the results as data tables. Other notebooks allow the user to reproduce all the analysis underlying this work, including reproducing the figures and many of the tables.

microbiology↗

Accessing anti-HIV activity through the attenuation of USP18 activity: novel insights from molecular dynamic simulations, free-energy profiling, and multi-cellular inhibition assays

The feasibility of achieving anti-HIV activity from the attenuation of USP18 activity was explored for the first time. A cheminformatic survey demonstrated that the current known USP18 isopeptidase inhibitors are derivatives of a bis-aryl pyranone scaffold that possesses undesirable toxicity profiles. Molecular modelling approaches applied to these active bis-aryl pyranones isolated the likely mechanism that perturbs the isopeptidase activity of USP18. Molecular dynamic simulations and free-energy profiling showed that induced-fit effects on the catalytic triad and the IBB-1 domain residues of USP18 drive a reversible non-competitive isopeptidase inhibition mechanism. Proof-of-concept multi-cellular HIV inhibition assays demonstrate the utility of achieving anti-HIV-1 activity from attenuating the activity of USP18 using small molecules. This study motivates for the pursuit of scaffolds that target the allosteric site of USP18, fine-tuning the IFN response as a strategy to enhance the natural control mechanisms that lead to an antiviral state potentially curing viral infection.

immunology↗

Mycobacterium tuberculosis senses host Interferon- gamma via the membrane protein MmpL10

Mycobacterium tuberculosis (Mtb) is one of the most successful human pathogens and remains a leading cause of death from infectious disease. Interferon-{gamma} (IFN-{gamma}) is a central regulator of the immune defense against Mtb. Several cytokines have been shown to increase virulence of other bacterial pathogens, leading us to investigate whether IFN-{gamma} has a direct effect on Mtb. We found that both recombinant and T-cell derived IFN-{gamma} rapidly induced a dose-dependent increase in the oxygen consumption rate (OCR) of Mtb, consistent with increased bacterial respiration. This was also observed in clinical strains, but not in the vaccine strain Bacillus Calmette-Guerin (BCG), and did not occur for other cytokines tested, including TNF-. IFN-{gamma} binds to the cell surface of intact Mtb, but not BCG, whilst TNF- binds to neither. Mass spectrometry analysis identified mycobacterial membrane protein large 10 (MmpL10) as the transmembrane binding partner. Consistent with this, IFN-{gamma} binding and the OCR response was absent in a Mtb {Delta}mmpl10 strain and restored by complementation of the mutant strain. RNA-sequencing of IFN-{gamma} exposed Mtb revealed a distinct transcriptional profile, including genes involved in virulence and cholesterol catabolism. Finally, exposure of Mtb cells to IFN-{gamma} resulted in sterilization of bacilli treated with isoniazid (INH), indicating clearance of phenotypically resistant bacteria that persist in the presence of INH alone. Our data suggest a novel mechanism allowing Mtb to respond to host immune activation that may be important in the immunopathogenesis of TB and have use in novel eradication strategies. One-Sentence SummaryIFN-{gamma} is a critical component of effective immune defense in human tuberculosis yet its causative agent, Mycobacterium tuberculosis it able to sense this cytokine and increase virulence and respiration in response.

microbiology↗

The CNS in the face of ART contains T cell origin HIV which can lead to drug resistance

HIV persists despite antiretroviral therapy (ART) in cellular reservoirs thought to occur in distinct anatomical compartments. Therapy failure may occur because of incomplete ART adherence and possibly viral replication at some reservoir sites. The CNS may serve as a reservoir site due to lowered ART penetration and virus production from long-lived tissue resident macrophages. Compelling evidence for the CNS as a reservoir is the existence of individuals where HIV is suppressed below limit of detection in blood but detectable in the cerebrospinal fluid (CSF), termed CSF Escape. Here, we asked whether HIV in CSF Escape individuals is derived from macrophages or persists due to lowered ART. We used cell surface markers on the HIV envelope to determine the cellular source of HIV. We verified detection using in vitro derived virus from infected macrophages and T cells and tested CSF from CSF Escape individuals. We observed host surface markers consistent with T cell origin. We also measured ART concentrations in the CSF and plasma. We found a dramatic decrease in CSF ART concentrations described previously, but no significant difference between CSF Escape versus fully suppressed individuals. To examine the effect of the observed CSF ART concentrations on HIV replication, we used long-term infection with ART in cell culture. CSF Escape ART levels led to either HIV suppression or evolution of drug resistance, but not replication of drug sensitive HIV. These observations argue that persistent CNS viremia despite ART can be T cell generated and may result in drug resistance and therapy failure.

microbiology↗